Company intelligence / Profile preview
Nutrinia
Ramat Gan, Israelnutrinia.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company developed an oral insulin formulation that acts locally in the gut rather than systemically. The insulin binds to receptors in the gastrointestinal tract to stimulate intestinal villi and microvilli, helping to rehabilitate the bowel. The company had shown efficacy and safety in animal studies and multiple human clinical trials as of 2016.
- Therapeutic areas
- Gastroenterology
- Modalities
- Oral insulin formulation
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Nutrinia.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nutrinia.